Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of naringenin in preparation of medicine for curing pneumonia

A technology of naringenin and pneumonia, applied in the field of medicine, can solve the problems of reduced efficacy, high incidence of pneumonia and high mortality

Active Publication Date: 2013-01-16
HUBEI WUDANG ANIMAL PHARMA
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinically, the morbidity and mortality of pneumonia caused by Staphylococcus aureus infection are still high, and the effectiveness of traditional antibiotics in the treatment of pneumonia caused by drug-resistant Staphylococcus aureus is gradually decreasing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of naringenin in preparation of medicine for curing pneumonia
  • Application of naringenin in preparation of medicine for curing pneumonia
  • Application of naringenin in preparation of medicine for curing pneumonia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0007] 1. Hemolysis test

[0008] Staphylococcus aureus culture Then co-culture with different concentrations of naringenin until the late logarithmic growth period, harvest the bacterial liquid and centrifuge to get the supernatant. The culture supernatants of different drug concentrations were mixed with diluted rabbit defibrotic red blood cells, and incubated at 37°C for 10-20 minutes. Centrifuge to measure the absorbance of the supernatant.

[0009] The percentage of hemolysis after adding different concentrations of naringenin is shown in Table 1:

[0010] Table 1. Supernatant hemolysis of ATCC 29213, ATCC 10832, 8325-4 and BAA-1717 in cultures without treatment and with different concentrations of naringenin

[0011]

[0012] a The hemolysis effect of the culture supernatant of Staphylococcus aureus in the drug-untreated group on rabbit erythrocytes was set as 100% hemolysis: none means that hemolysis was observed;

[0013] The t test was used to analyze the dif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of naringenin in the preparation of medicine for curing pneumonia. The effect in staphylococcus aureus infection curing is proved through a rabbit erythrocyte hemolytic test, a pulmonary epithelial cell (A549) damage protection test and a mouse staphylococcus aureus pulmonary inflammation model. Compared with antibiotic therapy, naringenin therapy has the characteristics of no drug tolerance and high cure rate.

Description

technical field [0001] The invention relates to the application of naringenin in the preparation of medicines for treating pneumonia, which belongs to the field of medicine. 1. Background Technology [0002] Naringenin (naringenin, Nar, 4, 5, 7-trihydroxyflavanone) is a monomer extracted from pomelo, a Rutaceae plant, and belongs to flavonoids. It is widely found in lemon, grape juice, orange Among them, it has strong free radical scavenging, anti-oxidation, anti-inflammation, anti-atherosclerosis, anti-fibrosis, cell protection, and various pharmacological effects such as antibacterial, anti-inflammatory, and anti-tumor, but it has not yet been used as a drug. in the clinic. [0003] Bacterial pneumonia is caused by Streptococcus pneumoniae (Pneumococcus), Staphylococcus aureus, Hemolytic Streptococcus, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Escherichia coli, Pseudomonas aeruginosa Diseases caused by infections such as bacilli. In recent y...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P11/00A61P31/04A61P31/10
Inventor 邓旭明张雨邱家章鲁崇建
Owner HUBEI WUDANG ANIMAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com